Overview
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Indication
For the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable.
Associated Conditions
- Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/05/07 | N/A | Not yet recruiting | Zeenat Qureshi Stroke Institute | ||
2023/10/03 | Phase 4 | Not yet recruiting | |||
2023/06/28 | Phase 3 | Not yet recruiting | |||
2023/03/24 | Phase 3 | Not yet recruiting | |||
2022/01/03 | Phase 3 | Completed | ProMedica Health System | ||
2021/12/23 | N/A | Completed | Hospital de Cruces | ||
2020/12/17 | Phase 3 | UNKNOWN | Nanjing Yoko Biomedical Co., Ltd. | ||
2018/10/25 | Early Phase 1 | Completed | |||
2017/10/03 | Phase 4 | Withdrawn | |||
2013/12/13 | Phase 2 | Withdrawn |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Chiesi USA, Inc. | 10122-611 | INTRAVENOUS | 0.5 mg in 1 mL | 9/6/2022 | |
| Fresenius Kabi Austria GmbH | 18124-011 | INTRAVENOUS | 0.5 mg in 1 mL | 12/28/2018 | |
| Chiesi USA, Inc. | 10122-610 | INTRAVENOUS | 0.5 mg in 1 mL | 9/6/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| CLEVIPREX clevidipine, 50 mg in 100 mL injectable emulsion, Single Use Vials | 203314 | Medicine | A | 6/27/2013 | |
| CLEVIPREX clevidipine, 25 mg in 50 mL injectable emulsion, Single Use Vials | 203313 | Medicine | A | 6/27/2013 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| CLEVIPREX | 02366223 | Emulsion - Intravenous | 0.5 MG / ML | 8/4/2023 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| CLEVIPREX 0,5MG/ML EMULSION INYECTABLE | Chiesi España S.A.U. | 76595 | EMULSIÓN INYECTABLE | Uso Hospitalario | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.